Landos Biopharma LABP

$ 22.93 0.58%

Annual report 2023
added 03-21-2024

Landos Biopharma Financial Statements 2011-2024 | LABP

Annual Financial Statements Landos Biopharma

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	48.1 M	1.05 M	129 M	-	-	-	-	-	-	-	-	-	-
Shares	6.28 M	4.03 M	37.6 M	-	-	-	-	-	-	-	-	-	-
Historical Prices	7.67	0.26	3.43	-	-	-	-	-	-	-	-	-	-
Net Income	-21.9 M	-39.3 M	-38.4 M	-30.1 M	-13.5 M	-6.04 M	-	-	-	-	-	-	-
Revenue	-	-	18 M	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-22.7 M	-40.6 M	-38.8 M	-30.7 M	-	-	-	-	-	-	-	-	-
Interest Expense	1.2 M	1.28 M	394 K	532 K	-	-	-	-	-	-	-	-	-
EBITDA	-	-40 M	-38.6 M	-	-13 M	-5.85 M	-	-	-	-	-	-	-
Operating Expenses	22.7 M	40.6 M	56.8 M	30.7 M	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	10.7 M	14.9 M	15.3 M	5.34 M	1.48 M	1.14 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Landos Biopharma

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	6.21 M	6.21 M	64.8 M	4.03 M	4.03 M	4.03 M	40.3 M	40.3 M	40 M	33.6 M	26.1 M	12.8 M	12.3 M	12.1 M	11.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-5.86 M	-3.92 M	-6.03 M	-	-7.9 M	-11.3 M	-14.9 M	-	-12.6 M	4.1 M	-9.82 M	-	-8.23 M	-4.78 M	-5.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	18 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-5.2 M	-4.44 M	-6.48 M	-	-7.83 M	-11.3 M	-15 M	-	-12.4 M	3.88 M	-9.9 M	-	-8.42 M	-5.09 M	-5.77 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-661 K	517 K	445 K	-	-67 K	-18 K	89 K	-	-201 K	215 K	82 K	-	189 K	-311 K	-26 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-7.83 M	-11 M	-14.6 M	-	-12.4 M	3.93 M	-9.86 M	-	-8.32 M	-5.02 M	-5.74 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	5.2 M	4.44 M	6.48 M	-	7.83 M	11.3 M	15 M	-	12.4 M	14.1 M	9.9 M	-	8.42 M	5.09 M	5.77 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	2.14 M	1.98 M	3.15 M	-	2.97 M	4.66 M	4.15 M	-	3.06 M	2.6 M	2.65 M	-	1.45 M	1.36 M	1.08 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency